Tocilizumab Linked to Lower Lung Failure Risk

A retrospective study of patients with systemic sclerosis-associated interstitial lung disease compared tocilizumab with nintedanib over five years.

Updated on Nov. 9, 2026 in Asthma

Tocilizumab Linked to Lower Lung Failure Risk

Tocilizumab was associated with a lower risk of respiratory failure and modestly lower five-year mortality than nintedanib among patients with systemic sclerosis-associated interstitial lung disease. The findings come from a retrospective cohort analysis presented at ACR Convergence 2026.

Why it matters

Nintedanib is a standard antifibrotic treatment, and these results suggest an immune-targeting alternative may offer benefits over time in this disease. Because the study is retrospective, the findings point to a possible advantage that would need confirmation in controlled trials.

The retrospective cohort analysis matched 765 adults per group and found 5-year mortality of 11.8% with tocilizumab versus 15.3% with nintedanib, and 5-year respiratory failure of 25.0% versus 32.8%. Whether these differences hold in prospective randomized trials remains unknown.

The players

ACR Convergence 2026

The annual meeting of the American College of Rheumatology, where clinical and research findings in rheumatology are presented to specialists.

The details

Researchers used TriNetX Global Collaborative Network data to compare adults with systemic sclerosis-associated interstitial lung disease treated with tocilizumab, an interleukin-6 receptor antagonist, against those treated with nintedanib, an intracellular tyrosine kinase inhibitor. After propensity score matching, differences in mortality and respiratory failure were not significant at one year but favored tocilizumab by two and five years.

Timeline

  1. One year: mortality and respiratory failure rates were not significantly different between groups.

  2. Two years: the difference in respiratory failure became statistically significant, favoring tocilizumab.

  3. Five years: mortality and respiratory failure differences both favored tocilizumab significantly.

  4. November 6-11, 2026: findings were presented at the ACR Convergence 2026 meeting in Orlando, Florida.

Health Landscape

The findings add to a growing body of evidence weighing immune-targeted therapies against nintedanib, the established antifibrotic for systemic sclerosis-associated interstitial lung disease. They highlight how long-term outcomes such as respiratory failure may diverge from early results in this progressive disease.

Patients with systemic sclerosis-associated interstitial lung disease may wish to discuss these long-term findings with their rheumatologist when weighing treatment options. The results are observational, so they do not by themselves change standard care.

The takeaway

Long-term outcomes can differ from early results, so the five-year picture is worth weighing alongside short-term data. Patients and clinicians should await prospective trial confirmation before changing established treatment plans.

Further reading

For more on lung disease treatment, see the Asthma section.